XML 62 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
SEGMENT REPORTING
12 Months Ended
Dec. 31, 2014
Notes to Financial Statements  
SEGMENT REPORTING
10.SEGMENT REPORTING

The Company is comprised of two reportable segments, Core Companion Animal Health ("CCA") and Other Vaccines, Pharmaceuticals and Products ("OVP"). The Core Companion Animal Health segment includes diagnostic instruments and supplies, as well as single use diagnostic and other tests, pharmaceuticals and vaccines, primarily for canine and feline use. The CCA segment also includes digital radiography and ultrasound products along with embedded software and support, data hosting and other services from Heska Imaging after February 24, 2013. These products are sold directly by the Company as well as through independent third-party distributors and through other distribution relationships. CCA segment products manufactured at the Des Moines, Iowa production facility included in the OVP segment's assets are transferred at cost and are not recorded as revenue for the OVP segment. The Other Vaccines, Pharmaceuticals and Products segment includes private label vaccine and pharmaceutical production, primarily for cattle, but also for other animals including small mammals. All OVP products are sold by third parties under third-party labels.

 

Summarized financial information concerning the Company's reportable segments is shown in the following table (in thousands):

 

 

    Core Companion Animal Health   Other Vaccines, Pharmaceuticals and Products  

 

 

Total

 
  2012:                  
  Total revenue $ 61,502   $ 11,303   $ 72,805  
  Operating income   1,160     998     2,158  
  Interest expense   91     26     117  
  Total assets   55,071     11,755     66,826  
  Net assets   39,726     9,136     48,862  
  Capital expenditures   634     875     1,509  
  Depreciation and amortization   862     837     1,699  

 

    Core Companion Animal Health   Other Vaccines, Pharmaceuticals and Products    

 

 

Total

 
  2013:                  
  Total revenue $ 66,404   $ 11,935   $ 78,339  
  Operating income (loss)   (2,295 )   865     (1,430 )
  Interest expense   45     29     74  
  Total assets   81,041     12,512     93,553  
  Net assets   37,732     9,384     47,116  
  Capital expenditures   512     1,418     1,930  
  Depreciation and amortization   1,691     806     2,497  

 

    Core Companion Animal Health   Other Vaccines, Pharmaceuticals and Products  

 

 

Total

 
  2014:                  
  Total revenue $ 72,354   $ 17,483   $ 89,837  
  Operating income (loss)   1,198     1,713     2,911  
  Interest expense   153     53     206  
  Total assets   85,361     11,483     96,844  
  Net assets   44,520     8,612     53,132  
  Capital expenditures   1,864     473     2,337  
  Depreciation and amortization   2,954     758     3,712  

 

 

Total revenue by principal geographic area was as follows (in thousands):

 

    For the Years Ended December 31,  
    2012   2013   2014  
  United States $ 64,552   $ 71,713   $ 83,584  
  Europe   2,996     2,738     2,264  
  Other International   5,257     3,888     3,989  
  Total $ 72,805   $ 78,339   $ 89,837  

 

 

 

Total assets by principal geographic areas were as follows (in thousands):

 

    For the Years Ended December 31,  
    2012   2013   2014  
  United States $ 63,980   $ 90,572   $ 93,977  
  Europe   2,846     2,981     2,867  
  Other International            
  Total $ 66,826   $ 93,553   $ 96,844